Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.
Psallidas I, Backer V, Kuna P, Palmér R, Necander S, Aurell M, Korsback K, Taib Z, Hashemi M, Gustafson P, Asimus S, Delaney S, Pardali K, Jiang F, Almquist J, Jackson S, Coffman RL, Keeling D, Sethi T. Psallidas I, et al. Among authors: hashemi m. Am J Respir Crit Care Med. 2021 Feb 1;203(3):296-306. doi: 10.1164/rccm.202001-0133OC. Am J Respir Crit Care Med. 2021. PMID: 32809843 Clinical Trial.
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.
Hegelund Myrbäck T, Prothon S, Edman K, Leander J, Hashemi M, Dearman M, Edenro G, Svanberg P, Andersson EM, Almquist J, Ämmälä C, Hendrickx R, Taib Z, Johansson KA, Berggren AR, Keen CM, Eriksson UG, Fuhr R, Carlsson BCL. Hegelund Myrbäck T, et al. Among authors: hashemi m. Lancet Rheumatol. 2020 Jan;2(1):e31-e41. doi: 10.1016/S2665-9913(19)30103-1. Epub 2019 Dec 9. Lancet Rheumatol. 2020. PMID: 38258274
Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
Sadiq MW, Asimus S, Belvisi MG, Brailsford W, Fransson R, Fuhr R, Hagberg A, Hashemi M, Jellesmark Jensen T, Jonsson J, Keen C, Körnicke T, Kristensson C, Mäenpää J, Necander S, Nemes S, Betts J. Sadiq MW, et al. Among authors: hashemi m. Br J Clin Pharmacol. 2022 Jan;88(1):260-270. doi: 10.1111/bcp.14956. Epub 2021 Aug 8. Br J Clin Pharmacol. 2022. PMID: 34182611 Free article. Clinical Trial.
Nanoscale Interaction of Endonuclease APE1 with DNA.
Vemulapalli S, Hashemi M, Chen Y, Pramanik S, Bhakat KK, Lyubchenko YL. Vemulapalli S, et al. Among authors: hashemi m. Int J Mol Sci. 2024 May 9;25(10):5145. doi: 10.3390/ijms25105145. Int J Mol Sci. 2024. PMID: 38791183 Free PMC article.
Development of fast-dissolving sublingual nanofibers containing allergen and curcumin for immune response modulation in a mouse model of allergic rhinitis.
Ansari B, Abbaspour MR, Estajy A, Haghnavaz N, Pordel S, Rezaee M, Shobeiri SS, Moghadam M, Hashemi M, Sankian M. Ansari B, et al. Among authors: hashemi m. Naunyn Schmiedebergs Arch Pharmacol. 2024 May 14. doi: 10.1007/s00210-024-03139-y. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38743115
1,349 results